Research Highlight | Published:


Alliance to iLLUMINATE the chemo-free sign

Nature Reviews Clinical Oncologyvolume 16page65 (2019) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


    Original articles

    1. Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol. (2018)

    2. Woyach, J. A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. (2018)

    3. Burger, J. A. et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood (2018)

    Download references

    Author information


    1. Nature Reviews Clinical Oncology

      • Diana Romero


    1. Search for Diana Romero in:

    Corresponding author

    Correspondence to Diana Romero.

    About this article

    Publication history



    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing